Robin L. Jones, BSc, MB BS, MRCP, MD

Consultant Medical Oncologist
Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
London, England, United Kingdom

Disclosure information not submitted.

Presentation(s):

• Paper 04 - THE PATIENT-REPORTED OUTCOMES (PROS) IN SARCOMA INITIATIVE: TOWARDS A GLOBAL COLLABORATIVE MEASUREMENT STRATEGY

  Thursday, November 2, 2023
  9:00 AM – 10:00 AM  

• Paper 24 - MILADEMETAN VS. TRABECTEDIN IN PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: RESULTS FROM THE PHASE 3 MANTRA STUDY

  Thursday, November 2, 2023
  4:00 PM – 5:30 PM  

• Paper 48 - PROTEOMIC FEATURES OF ADOLESCENTS AND YOUNG ADULTS WITH SOFT TISSUE SARCOMAS

  Friday, November 3, 2023
  2:30 PM – 4:00 PM  

• Debate #2: Drugs that have not received regulatory approvals in sarcomas should not be used to treat sarcoma patients except on a clinical trial

  Friday, November 3, 2023
  12:30 PM – 1:00 PM  

• Paper 61 - INSIGHT: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR PREVIOUSLY TREATED WITH IMATINIB WITH KIT EXON 11+17/18 MUTATIONS

  Saturday, November 4, 2023
  9:00 AM – 10:00 AM  

• Paper 62 - PEAK STUDY: A PHASE 3, RANDOMIZED, OPEN-LABEL MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB COMBINATION VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST)

  Saturday, November 4, 2023
  9:00 AM – 10:00 AM